Eli Lilly's Combination Therapy Shows Efficacy in Psoriatic Arthritis Trial

Eli Lilly announced positive 52-week results from its Phase IIIb TOGETHER-PsA trial. The study evaluated Taltz and Zepbound in combination for active psoriatic arthritis in adults with overweight or obesity. The therapy demonstrated superior efficacy compared to Taltz alone, with 39.2% of patients achieving an ACR50 response and at least a 10% body weight reduction at week 36, indicating potential for improved treatment outcomes.